| Expression pattern: |
UP |
| Associated gene: |
HIF1alpha, LDHA, VEGFR, VEGF, EGFR |
| Associated microRNA: |
- |
| Biological function: |
Promotes bladder cancer cell growth and proliferation, inhibits apoptosis, promotes invasion, promotes LDHA-mediated aerobic glycolysis, and reduces sensitivity to glycolytic inhibitors. |
| Molecular mechanism: |
HIF1alpha induces has-circRNA-403658; has-circRNA-403658 interacts with LDHA and positively regulates LDHA promoter activity and LDHA expression, thereby promoting LDHA-mediated aerobic glycolysis and bladder cancer progression. |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); invasion (promotes); glycolysis (promotes); drug resistance (promotes); angiogenesis (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Clinical Sample Validation; Transfection; BrdU; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; ELISA; Survival Analysis; Cohort Study; Bioinformatics Analysis |
| Clinical significance: |
Higher has-circRNA-403658 levels were associated with poorer survival outcome and with tumor size, distant metastasis and TNM stage; has_circRNA_403658 was an independent prognostic factor in bladder cancer. |
| Description: |
has-circRNA-403658/cZNF292 is a hypoxia-inducible circRNA derived from ZNF292 that is upregulated in bladder cancer tissues and hypoxic bladder cancer cells. It promotes bladder cancer growth, proliferation, invasion and aerobic glycolysis while inhibiting apoptosis, at least partly through interaction with and activation of LDHA. High expression is associated with poorer overall survival and adverse clinicopathological features, suggesting prognostic and therapeutic relevance. |
| Confidence score: |
0.8226 |